Nevertheless, SSLs remain critical targets for CRC prevention due to their molecular heterogeneity (e.g., BRAF mutations and CIMP-H) and substantial contribution to post-colonoscopy CRC (PCCRC), accounting for 18%-20% of cases (4, 15). The gene discussed is BRAF; the disease is colorectal carcinoma.